FR2385688B1 - - Google Patents

Info

Publication number
FR2385688B1
FR2385688B1 FR7808850A FR7808850A FR2385688B1 FR 2385688 B1 FR2385688 B1 FR 2385688B1 FR 7808850 A FR7808850 A FR 7808850A FR 7808850 A FR7808850 A FR 7808850A FR 2385688 B1 FR2385688 B1 FR 2385688B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7808850A
Other languages
French (fr)
Other versions
FR2385688A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of FR2385688A1 publication Critical patent/FR2385688A1/fr
Application granted granted Critical
Publication of FR2385688B1 publication Critical patent/FR2385688B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/16Somatostatin; related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/26Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7808850A 1977-03-28 1978-03-28 Nouveaux peptides a activite biologique Granted FR2385688A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/781,580 US4105603A (en) 1977-03-28 1977-03-28 Peptides which effect release of hormones

Publications (2)

Publication Number Publication Date
FR2385688A1 FR2385688A1 (fr) 1978-10-27
FR2385688B1 true FR2385688B1 (cg-RX-API-DMAC7.html) 1983-10-07

Family

ID=25123228

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7808850A Granted FR2385688A1 (fr) 1977-03-28 1978-03-28 Nouveaux peptides a activite biologique

Country Status (19)

Country Link
US (1) US4105603A (cg-RX-API-DMAC7.html)
JP (1) JPS53130687A (cg-RX-API-DMAC7.html)
AT (1) AT366026B (cg-RX-API-DMAC7.html)
AU (1) AU519122B2 (cg-RX-API-DMAC7.html)
BE (1) BE865380A (cg-RX-API-DMAC7.html)
CA (1) CA1102314A (cg-RX-API-DMAC7.html)
CH (1) CH639361A5 (cg-RX-API-DMAC7.html)
DE (1) DE2813327A1 (cg-RX-API-DMAC7.html)
DK (1) DK131878A (cg-RX-API-DMAC7.html)
ES (1) ES468241A1 (cg-RX-API-DMAC7.html)
FI (1) FI780907A7 (cg-RX-API-DMAC7.html)
FR (1) FR2385688A1 (cg-RX-API-DMAC7.html)
GB (1) GB1564191A (cg-RX-API-DMAC7.html)
IE (1) IE46862B1 (cg-RX-API-DMAC7.html)
IT (1) IT1105152B (cg-RX-API-DMAC7.html)
LU (1) LU79320A1 (cg-RX-API-DMAC7.html)
NL (1) NL7803289A (cg-RX-API-DMAC7.html)
SE (1) SE446190B (cg-RX-API-DMAC7.html)
ZA (1) ZA781599B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211693A (en) * 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
US4185010A (en) * 1978-12-12 1980-01-22 American Home Products Corporation Nonapeptides
US4225472A (en) * 1979-05-29 1980-09-30 American Home Products Corporation Truncated somatostatin analogs
USRE30548E (en) * 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
ATE2512T1 (de) * 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
FR2523125A1 (fr) * 1982-03-08 1983-09-16 Sanofi Sa Analogues de la somatostatine a activite biologique modifiee et medicaments en contenant
US4428942A (en) 1982-05-17 1984-01-31 The Salk Institute For Biological Studies Analogs of somatostatin
US4443368A (en) * 1982-11-01 1984-04-17 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
ATE122357T1 (de) * 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO2001010892A2 (en) * 1999-08-06 2001-02-15 Genentech, Inc. Peptide antagonists of factor viia
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
CA2569692C (en) * 2004-06-07 2015-07-21 Raven Biotechnologies, Inc. Transferrin receptor antibodies
JP2008515889A (ja) * 2004-10-05 2008-05-15 ジェネンテック・インコーポレーテッド 毒性の低下した治療剤
JP2008526256A (ja) 2005-01-12 2008-07-24 レイベン バイオテクノロジーズ,インコーポレイティド Kid31およびkid31に結合する抗体
WO2006083852A2 (en) * 2005-01-31 2006-08-10 Raven Biotechnologies, Inc. Luca2 and antibodies that bind thereto
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド Adam−9モジュレータ
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
AU2006210606B2 (en) * 2005-02-03 2012-03-22 Macrogenics West, Inc. Antibodies to Oncostatin M receptor
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
EP2094307A4 (en) * 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
WO2010123945A2 (en) 2009-04-20 2010-10-28 Allergan, Inc. Silk fibroin hydrogels and uses thereof
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2982380B1 (en) 2010-03-04 2021-09-01 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN107722124A (zh) 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
US8828928B2 (en) 2011-08-23 2014-09-09 President And Fellows Of Harvard College Amphiphilic peptides and peptide particles
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP3839044A1 (en) 2013-03-14 2021-06-23 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
WO2014154891A1 (en) 2013-03-29 2014-10-02 Centre National De La Recherche Scientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
RU2718692C2 (ru) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
ES2898958T3 (es) 2015-07-30 2022-03-09 Macrogenics Inc Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
EP3359192A4 (en) 2015-10-08 2019-05-01 MacroGenics, Inc. COMBINATION THERAPY FOR CANCER TREATMENT
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化lag3に対して特異的な抗体およびその使用方法
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904594A (en) * 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
US3917578A (en) * 1973-12-10 1975-11-04 Ayerst Mckenna & Harrison Process for producing somatostatin and intermediates
US3882098A (en) * 1974-01-03 1975-05-06 American Home Prod Synthesis of des-Ala{hu 1{b , Gly{hu 2{b , Asn{hu 5{b -SRIF and intermediates
US4011207A (en) * 1974-12-27 1977-03-08 American Home Products Corporation Des-(Ala1, Gly2,Lys4 -Srif, Des-(Ala1, Gly2, Lys4)-D-Trp8 -Srif and intermediates
US3933784A (en) * 1975-01-27 1976-01-20 American Home Products Corporation Des-(ser13)-srif and intermediates

Also Published As

Publication number Publication date
ATA213878A (de) 1981-07-15
ZA781599B (en) 1979-10-31
IT1105152B (it) 1985-10-28
CH639361A5 (de) 1983-11-15
ES468241A1 (es) 1978-12-01
NL7803289A (nl) 1978-10-02
JPS53130687A (en) 1978-11-14
IE46862B1 (en) 1983-10-19
GB1564191A (en) 1980-04-02
US4105603A (en) 1978-08-08
DE2813327C2 (cg-RX-API-DMAC7.html) 1988-08-18
DE2813327A1 (de) 1978-10-05
SE446190B (sv) 1986-08-18
DK131878A (da) 1978-09-29
CA1102314A (en) 1981-06-02
AT366026B (de) 1982-03-10
JPS6141920B2 (cg-RX-API-DMAC7.html) 1986-09-18
IT7848586A0 (it) 1978-03-23
IE780511L (en) 1978-09-28
BE865380A (fr) 1978-07-17
SE7803318L (sv) 1978-09-29
FI780907A7 (fi) 1978-09-29
AU3430778A (en) 1979-09-27
AU519122B2 (en) 1981-11-12
FR2385688A1 (fr) 1978-10-27
LU79320A1 (fr) 1978-06-29

Similar Documents

Publication Publication Date Title
FR2385688B1 (cg-RX-API-DMAC7.html)
FR2377047B3 (cg-RX-API-DMAC7.html)
FR2377588B1 (cg-RX-API-DMAC7.html)
FR2377301B1 (cg-RX-API-DMAC7.html)
FR2376915B1 (cg-RX-API-DMAC7.html)
DE2753104C2 (cg-RX-API-DMAC7.html)
FR2378166B1 (cg-RX-API-DMAC7.html)
DK142089C (cg-RX-API-DMAC7.html)
DK352877A (cg-RX-API-DMAC7.html)
DK326677A (cg-RX-API-DMAC7.html)
BG25847A1 (cg-RX-API-DMAC7.html)
BG26492A1 (cg-RX-API-DMAC7.html)
BG25828A1 (cg-RX-API-DMAC7.html)
BG25853A1 (cg-RX-API-DMAC7.html)
BG25826A1 (cg-RX-API-DMAC7.html)
BG25825A1 (cg-RX-API-DMAC7.html)
BG25824A1 (cg-RX-API-DMAC7.html)
BG25855A1 (cg-RX-API-DMAC7.html)
BG25823A1 (cg-RX-API-DMAC7.html)
BG25860A1 (cg-RX-API-DMAC7.html)
BG25822A1 (cg-RX-API-DMAC7.html)
BG25820A1 (cg-RX-API-DMAC7.html)
BG25819A1 (cg-RX-API-DMAC7.html)
BG25815A1 (cg-RX-API-DMAC7.html)
BG23462A1 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
ST Notification of lapse